

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>AH Equity Partners Bio II, L.L.C.</u>  (Last) (First) (Middle) C/O ANDREESSEN HOROWITZ 2865 SAND HILL ROAD, SUITE 101  (Street) MENLO PARK CA 94025  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Nautilus Biotechnology, Inc. [ NAUT ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 06/02/2026	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/02/2026		S		4,615,974	D	\$2.35	11,682,032	I	By AH Bio Fund II, L.P. <sup>(1)(2)</sup>
Common Stock	06/02/2026		S		384,026	D	\$2.35	971,885	I	By Andreesen Horowitz LSV Fund II, L.P. <sup>(3)(4)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person\*  
AH Equity Partners Bio II, L.L.C.  
 (Last) (First) (Middle)  
 C/O ANDREESSEN HOROWITZ  
 2865 SAND HILL ROAD, SUITE 101  
 (Street)  
 MENLO PARK CA 94025  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Andreesen Horowitz LSV Fund II, L.P.  
 (Last) (First) (Middle)  
 C/O ANDREESSEN HOROWITZ  
 2865 SAND HILL ROAD, SUITE 101

(Street)  
MENLO PARK CA 94025

---

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
[AH Bio Fund II, L.P.](#)

---

(Last) (First) (Middle)  
C/O ANDREESSEN HOROWITZ  
2865 SAND HILL ROAD, SUITE 101

---

(Street)  
MENLO PARK CA 94025

---

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
[AH Equity Partners LSV II, L.L.C.](#)

---

(Last) (First) (Middle)  
C/O ANDREESSEN HOROWITZ  
2865 SAND HILL ROAD, SUITE 101

---

(Street)  
MENLO PARK CA 94025

---

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
[Andreessen Marc L](#)

---

(Last) (First) (Middle)  
C/O ANDREESSEN HOROWITZ  
2865 SAND HILL ROAD, SUITE 101

---

(Street)  
MENLO PARK CA 94025

---

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
[HOROWITZ BENJAMIN A](#)

---

(Last) (First) (Middle)  
C/O ANDREESSEN HOROWITZ  
2865 SAND HILL ROAD, SUITE 101

---

(Street)  
MENLO PARK CA 94025

---

(City) (State) (Zip)

**Explanation of Responses:**

1. The reported securities are held by AH Bio Fund II, L.P. ("AH Bio Fund II"), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. ("AH EP Bio II") is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee.
2. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
3. The reported securities are held by Andreessen Horowitz LSV Fund II, L.P. ("AH LSV Fund II"), for itself and as nominee for Andreessen Horowitz LSV Fund II-B, L.P. and Andreessen Horowitz LSV Fund II-Q, L.P. AH Equity Partners LSV II, L.L.C. ("AH EP LSV II") is the general partner of AH LSV Fund II and has sole voting and dispositive power with regard to the securities held by AH LSV Fund II for itself and as nominee. The managing members of AH EP LSV II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH LSV Fund II for itself and as nominee.
4. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH LSV Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.

[AH Equity Partners Bio II, L.L.C., By /s/ Phil Hathaway, 06/04/2026](#)  
[Chief Operating Officer](#)  
[Andreessen Horowitz LSV Fund II, L.P., By AH Equity Partners LSV II, L.L.C., Its General Partner, By /s/ Phil Hathaway, Chief Operating Officer](#) [06/04/2026](#)

[AH Bio Fund II, L.P., By AH Equity Partners Bio II, L.L.C., Its General Partner, By /s/ Phil Hathaway, Chief Operating Officer](#) [06/04/2026](#)  
[AH Equity Partners LSV II, L.L.C., By /s/ Phil Hathaway, Chief Operating Officer](#) [06/04/2026](#)  
[/s/ Phil Hathaway, Attorney-in-Fact for Marc L. Andreessen](#) [06/04/2026](#)  
[/s/ Phil Hathaway, Attorney-in-Fact for Benjamin Horowitz](#) [06/04/2026](#)

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

## POWER OF ATTORNEY

The undersigned individual (the “**Reporting Person**”) hereby authorizes and designates each entity affiliated with AH Capital Management, L.L.C., or such other person or entity as is designated in writing by Marc Andreessen (the “**Designated Filer**”) as the beneficial owner to prepare and file on behalf of the Reporting Person individually, or jointly together with other reporting persons, any and all reports, notices, communications and other documents (including, but not limited to, reports on Schedule 13D, Schedule 13G, Form 13-F, Form 3, Form 4 and Form 5) that the Reporting Person may be required to file with the United States Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (together with the implementing regulations thereto, the “**Act**”) and the Securities Exchange Act of 1934, as amended (together with the implementing regulations thereto, the “**Exchange Act**”) (collectively, the “**Reports**”) with respect to the Reporting Person’s ownership of, or transactions in, securities of any entity whose securities are beneficially owned (directly or indirectly) by the Reporting Person (collectively, the “**Companies**”).

The Reporting Person hereby further authorizes and designates Phil Hathaway (the “**Authorized Signatory**”) to execute and file on behalf of the Reporting Person the Reports and to perform any and all other acts, which in the opinion of the Designated Filer or Authorized Signatory may be necessary or incidental to the performance of the foregoing powers herein granted.

The authority of the Designated Filer and the Authorized Signatory under this Document with respect to the Reporting Person shall continue until the Reporting Person is no longer required to file any Reports with respect to the Reporting Person’s ownership of, or transactions in, the securities of the Companies, unless earlier revoked in writing. The Reporting Person acknowledges that the Designated Filer and the Authorized Signatory are not assuming any of the Reporting Person’s responsibilities to comply with the Act or the Exchange Act.

June 23, 2023

By: /s/ Marc Andreessen  
Marc Andreessen

## POWER OF ATTORNEY

The undersigned individual (the "**Reporting Person**") hereby authorizes and designates each entity affiliated with AH Capital Management, L.L.C., or such other person or entity as is designated in writing by Benjamin Horowitz (the "**Designated Filer**") as the beneficial owner to prepare and file on behalf of the Reporting Person individually, or jointly together with other reporting persons, any and all reports, notices, communications and other documents (including, but not limited to, reports on Schedule 13D, Schedule 13G, Form 13-F, Form 3, Form 4 and Form 5) that the Reporting Person may be required to file with the United States Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (together with the implementing regulations thereto, the "**Act**") and the Securities Exchange Act of 1934, as amended (together with the implementing regulations thereto, the "**Exchange Act**") (collectively, the "**Reports**") with respect to the Reporting Person's ownership of, or transactions in, securities of any entity whose securities are beneficially owned (directly or indirectly) by the Reporting Person (collectively, the "**Companies**").

The Reporting Person hereby further authorizes and designates Phil Hathaway (the "**Authorized Signatory**") to execute and file on behalf of the Reporting Person the Reports and to perform any and all other acts, which in the opinion of the Designated Filer or Authorized Signatory may be necessary or incidental to the performance of the foregoing powers herein granted.

The authority of the Designated Filer and the Authorized Signatory under this Document with respect to the Reporting Person shall continue until the Reporting Person is no longer required to file any Reports with respect to the Reporting Person's ownership of, or transactions in, the securities of the Companies, unless earlier revoked in writing. The Reporting Person acknowledges that the Designated Filer and the Authorized Signatory are not assuming any of the Reporting Person's responsibilities to comply with the Act or the Exchange Act.

June 22, 2023

By: /s/ Benjamin Horowitz  
Benjamin Horowitz